SLC5A2 and atherosclerosis: However, it is noteworthy that some studies have provided evidence implying the magnitude of hHF risk reduction from the treatment with SGLT2 inhibitors may vary between patients with established atherosclerotic cardiovascular disease (ASCVD) and those without.